VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager ...

Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...

Cell line development plays a key role in the identification of biological targets and commercial manufacturing of biotherapeutics. Despite its importance, the process faces a number of challenges, ...

Over the past decade, biologics development has moved from artisanal experimentation to a data-driven, platform-based discipline. Analytical depth has improved. Process integration has matured. Yet ...

ATUM, a leading US-based contract research organization, selected to support stable clonal cell line generation to advance VERAXA’s lead BiTAC-TCE program toward IND/CTA-enabling activities ...

Traditional approaches to biologics production—relying on one-size-fits-all expression vectors and empirical process optimization—have led to inefficiencies in expression, scalability, and ...

Cell line development is a crucial step in the drug discovery and development pipeline. It is essential in the manufacturing of biologics, as well as for drug screening, disease modeling and studying ...

Advances in cell line engineering and microfluidic technologies offer substantial opportunities to shorten timelines in cell line development (CLD). However, as with any innovation, optimizing these ...

Cell line development continues to face technical and operational hurdles in transfection, clone selection, and media optimization. Manual screening, extended culture timelines, and fragmented data ...

WHO-origin Master and Working Cell Banks provide vaccine developers with a ready-to-use Vero cell substrate for licensing, purchase, and integrated CDMO programs ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, and Applied StemCell Corp. (ASC), a leader in induced pluripotent stem cell (iPSC) technology and genome ...